Pacira BioSciences
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Mid-pack momentum — held if you own it, not a fresh buy.
- Signal has read HOLD for 3 days.
- Recent price momentum is +50.8% on average (3-month/1-year).
- Short interest has fallen to 8.4% of float.
- Analyst tilt is Hold.
- Price is above its 20-day average and above its 60-day average.
- The 20-day average is above the 60-day average, a short-term uptrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-21 20:27 UTC
Data coverage: 6 of 6 factors. Missing data is not a zero score.
Valuation C
How expensive the stock is versus earnings, sales and its own 5-year history.
| P/E (TTM) | 39.2x | Better than 14% |
| Forward P/E | 33.8x | Better than 14% |
| Price / Sales | 2.0x | Better than 58% |
| P/E vs own 5-yr range | 44th pctl | Better than 65% |
Growth C-
How fast revenue, profit and free cash flow are compounding.
| Revenue CAGR (3Y) | 2.9% | Better than 38% |
| Net income CAGR (3Y) | -23.8% | Better than 15% |
| Free cash flow CAGR (3Y) | 5.9% | Better than 47% |
Profitability C+
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 79.4% | Better than 90% |
| Operating margin | 2.6% | Better than 28% |
| Net margin | 1.0% | Better than 29% |
| Return on equity | 1.0% | Better than 29% |
| Return on invested capital | 0.1% | Better than 28% |
Momentum A+
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | 47.9% | Better than 100% |
| 6-month return | 56.2% | Better than 96% |
| 12-month return (ex latest month) | 57.7% | Better than 87% |
| Distance below 52-week high | 0.5% | Better than 99% |
Financial Health A-
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 4.5x | Better than 84% |
| Debt to assets | 33.1% | Better than 36% |
| Interest coverage | 2.2x | Better than 38% |
| Free cash flow / net income | 1,942.9% | Better than 98% |
Analyst View F
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 0.0% | Better than 0% |
| Upside to average target | -4.6% | Better than 2% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 36.48
- Open
- 0.00
- Day range
- 0.00 - 0.00
- Avg price
- 0.00
- Volume
- 0
- Turnover
- 0
- Turnover ratei
- 0.00%
- Volume ratioi
- 0.00
- Amplitudei
- 0.00%
- 52-week rangei
- 18.80 - 36.67
Valuation
- P/Ei
- 228.00
- P/E (TTM)i
- 39.23
- P/Bi
- 2.05
- EPSi
- 0.16
- Book value / shi
- 17.77
- Net profit
- 6.42M
- Net assets
- 712.32M
Share structure
- Market cap
- 1.46B
- Float capi
- 1.44B
- Shares out
- 40.09M
- Float sharesi
- 39.53M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- --
0.5% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-23.08M net over the window
Short interest
- Shares short
- 3.35M
- % of floati
- 8.39%
- Days to coveri
- 3.91
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Pacira BioSciences (PCRX)?
Pacira BioSciences last traded at 36.48. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Pacira BioSciences's market cap?
About 1.46B.
What is the P/E ratio of Pacira BioSciences?
The trailing twelve-month P/E is 39.23, above its own 5-year average of 29.09 — in the middle of its historical range (44.45% percentile). See the Valuation tab for the full history.
Does Pacira BioSciences pay a dividend?
Pacira BioSciences does not currently pay a regular dividend.
Is Pacira BioSciences a buy according to analysts?
The consensus of 9 analysts is a Hold rating, with an average 12-month price target of 34.79, which implies 4.6% downside from the current price. This is not investment advice.
What is Pacira BioSciences's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Pacira BioSciences a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.
Quote time 2026-11-19 19:54:59 · For reference only, not investment advice and not tailored to your situation.
Pacira BioSciences discussion 0 comments